慢性尋常性乾癬(Chronic Plaque Psoriasis)の治療薬パイプライン動向（2015年上半期版）...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Chronic Plaque Psoriasis Overview 8
Therapeutics Development 9
Pipeline Products for Chronic Plaque Psoriasis – Overview 9
Pipeline Products for Chronic Plaque Psoriasis – Comparative Analysis 10
Chronic Plaque Psoriasis – Therapeutics under Development by Companies 11
Chronic Plaque Psoriasis – Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Chronic Plaque Psoriasis – Products under Development by Companies 15
Chronic Plaque Psoriasis – Companies Involved in Therapeutics Development 16
AbGenomics International, Inc. 16
Actelion Ltd 17
Almirall, S.A. 18
ApoPharma Inc. 19
Biotest AG 20
Boehringer Ingelheim GmbH 21
Can-Fite BioPharma Ltd. 22
Coherus BioSciences, Inc. 23
Covagen AG 24
Eli Lilly and Company 25
GlaxoSmithKline plc 26
Mitsubishi Tanabe Pharma Corporation 27
Novartis AG 28
OPKO Health, Inc. 29
Pfizer Inc. 30
Sandoz Inc. 31
Sun Pharmaceutical Industries Inc. 32
Takeda Pharmaceutical Company Limited 33
UCB S.A. 34
XenoPort, Inc. 35
Chronic Plaque Psoriasis – Therapeutics Assessment 36
Assessment by Monotherapy Products 36
Assessment by Target 37
Assessment by Mechanism of Action 39
Assessment by Route of Administration 41
Assessment by Molecule Type 43
Drug Profiles 45
AbGn-168H – Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
adalimumab biosimilar – Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
baricitinib – Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
BI-655066 – Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
certolizumab pegol – Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
CF-101 – Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
CJM-112 – Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
COVA-322 – Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
dimethyl fumarate – Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
etanercept biosimilar – Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
etanercept biosimilar – Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
GSK-2831781 – Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
ixekizumab – Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
lunacalcipol – Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
MT-1303 – Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
namilumab – Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
orilotimod – Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
PF-06263276 – Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
ponesimod – Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
tildrakizumab – Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
tregalizumab – Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
XP-23829 – Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Chronic Plaque Psoriasis – Recent Pipeline Updates 80
Chronic Plaque Psoriasis – Dormant Projects 102
Chronic Plaque Psoriasis – Discontinued Products 103
Chronic Plaque Psoriasis – Product Development Milestones 104
Featured News & Press Releases 104
Jul 16, 2014: Coherus Announces Initiation Of Phase 3 Trial Of CHS-0214 (Investigational Etanercept Biosimilar) In Chronic Plaque Psoriasis 104
Mar 28, 2012: Lilly’s Ixekizumab Met Primary Endpoint In Phase II Study In Patients With Chronic Plaque Psoriasis 104
Nov 24, 2011: Biotest Announces Completion Of Phase IIa Trial Of Tregalizumab In Chronic Plaque Psoriasis 106
Appendix 108
Methodology 108
Coverage 108
Secondary Research 108
Primary Research 108
Expert Panel Validation 108
Contact Us 109
Disclaimer 109